In this regard, a recent data analysis from a prospective LS database supports little benefit by performing HBSO before 40 years of age, and no measurable benefit for mortality in premenopausal carriers with pathogenetic MSH6 or PMS2 [93]. This evidence concerns the gene PMS2 and Leigh syndrome.